Amphastar director granted RSUs and stock options

Pierce Anthony T reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Pierce Anthony T reported acquisition or exercise transactions in this Form 4 filing.

Amphastar Pharmaceuticals director Anthony T. Pierce received equity compensation on July 9, 2026, consisting of 7,886 restricted stock units and 16,646 stock options. All RSUs and options vest on July 9, 2027, with the options exercisable at $19.02 per share and expiring on July 9, 2036. These are grants, not open‑market purchases or sales.

Insider Trade Summary

Grant/Award: 24,532 shares

Grant/Award 2 txns

Insider Pierce Anthony T

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F2	16,646	$0.00	$0.00
Grant/Award	Common Stock F1	7,886	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 16,646 contracts (Direct); Common Stock — 7,886 shares (Direct)

Footnotes (2)

1. F1. The reported shares are represented by restricted stock units, or RSUs, all of which vest on July 9, 2027.
2. F2. All of the shares subject to the option vest on July 9, 2027.

Key Figures

RSU grant: 7,886 shares Stock options granted: 16,646 options Option exercise price: $19.02 per share +3 more

6 metrics

RSU grant 7,886 shares Restricted stock units granted to Anthony T. Pierce on July 9, 2026

Stock options granted 16,646 options Stock Option (right to buy) granted to Pierce on July 9, 2026

Option exercise price $19.02 per share Conversion or exercise price of granted stock options

RSU vesting date July 9, 2027 All reported RSUs vest on this date

Option vesting date July 9, 2027 All shares subject to the option vest on this date

Option expiration July 9, 2036 Expiration date of the granted stock options

Key Terms

restricted stock units, Stock Option (right to buy), vest, exercise price

4 terms

restricted stock units financial

"The reported shares are represented by restricted stock units, or RSUs, all of which vest"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (right to buy) financial

"Stock Option (right to buy) with an exercise price of 19.0200 and expiration date"

vest financial

"All of the shares subject to the option vest on July 9, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"conversion_or_exercise_price of 19.0200 for the stock option grant"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Amphastar (AMPH) director Anthony T. Pierce receive?

Anthony T. Pierce received 7,886 restricted stock units and 16,646 stock options in Amphastar Pharmaceuticals. Both awards were granted as equity compensation on July 9, 2026, and represent additional potential ownership if vesting conditions are satisfied and options are exercised.

When do Anthony T. Pierce’s new Amphastar (AMPH) RSUs and options vest?

All of Anthony T. Pierce’s newly granted Amphastar equity awards vest on July 9, 2027. This single vesting date applies both to the 7,886 restricted stock units and the 16,646 stock options, meaning they become fully earned on that date if conditions are met.

What is the exercise price and term of Anthony T. Pierce’s Amphastar (AMPH) stock options?

Pierce’s newly granted Amphastar stock options cover 16,646 shares at an exercise price of $19.02 per share. These options expire on July 9, 2036, giving a ten‑year term from the grant date, with vesting scheduled for July 9, 2027.

Did Anthony T. Pierce buy or sell Amphastar (AMPH) shares in the market?

No open‑market trades are reported. The filing shows of RSUs and options at $0.00 per share, indicating compensation awards rather than purchases or sales, with no separate market transactions disclosed in this report.

How many Amphastar (AMPH) shares does Anthony T. Pierce hold from these new awards?

After the reported grants, Pierce holds 7,886 RSUs and 16,646 stock options directly related to this award. The RSUs represent future common shares upon vesting, while the options represent the right to buy the same number of shares at $19.02 after vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 07:38 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pierce Anthony T

(Last) (First) (Middle)

C/O AMPHASTAR PHARMACEUTICALS, INC.

11570 6TH STREET

(Street)

RANCHO CUCAMONGA CALIFORNIA 91730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amphastar Pharmaceuticals, Inc. [ AMPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		A		7,886(1)	A	$0	7,886	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$19.02	07/09/2026		A		16,646		(2)	07/09/2036	Common Stock	16,646	$0	16,646	D

Explanation of Responses:

1. The reported shares are represented by restricted stock units, or RSUs, all of which vest on July 9, 2027.

2. All of the shares subject to the option vest on July 9, 2027.

	/s/ Eva Wen, by power of attorney	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)